ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
24/02/24
[PDF] Exploring the Prevalence and Characteristics of Obstructive Sleep Apnea Among Idiopathic Pulmonary Fibrosis Patients: A Systematic Review and Meta-Analysis
CR Wei, I Jalali, J Singh, A Nagaraj, MA Dari, MM Gdey… - Cureus, 2024
… In conclusion, our meta-analysis, comprising 411 idiopathic pulmonary fibrosis (IPF) patients from seven studies, reveals a significant prevalence of obstructive sleep apnea (OSA) in this population, reaching 70% (95% CI: 59 to 82%). Notably, OSA …
- 特発性肺線維症患者における閉塞性睡眠時無呼吸症候群の有病率と特徴の探求：系統的レビューとメタアナリシス
Identification of Idiopathic Pulmonary Fibrosis and Prediction of Disease Severity via Machine Learning Analysis of Comprehensive Metabolic Panel and Complete …
AN Mueller, HA Miller, MJ Taylor, SA Suliman… - Lung, 2024
… Idiopathic pulmonary fibrosis (IPF), the most common form of … of IPF can vary, with some patients experiencing rapid progression with exacerbations, resulting in the sudden loss of 20–30% of lung capacity, while others demonstrate a more …
[PDF] Abnormal collagen structure resulting from lack of contribution of collagen type XIV in lungs of patients with idiopathic pulmonary fibrosis
M Nizamoglu
… idiopathic pulmonary fibrosis (IPF). Increased collagen deposition in lung ECM is accompanied by altered collagen organization. Collagen type XIV, a fibril-associated collagen, supports collagen fibril organization. Its status in IPF … tissue sections …
- 特発性肺線維症患者の肺における XIV 型コラーゲンの寄与の欠如に起因する異常なコラーゲン構造
Profiling the Immune Landscape in Idiopathic Pulmonary Fibrosis with a Focus on Macrophages
HC Chau - 2023
… Overall, this review aims to outline IPFregarding macrophage and fibroblast interactions, in addition to the therapeutic roles that macrophages may play in becoming an inhibitory target for IPF. Idiopathic pulmonaryfibrosis (IPF) is a chronic …
- マクロファージに焦点を当てた特発性肺線維症における免疫状況のプロファイリング
[HTML] The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease—A Systematic Review
R Puiu, NS Motoc, S Lucaciu, MV Ruta… - Biomolecules, 2024
… From the interstitial lung disease family, we included research on idiopathic pulmonaryfibrosis, hypersensitivity pneumonitis and sarcoidosis. We included studies that used either method of evaluating the bacterial load from culture based …
- 線維性間質性肺疾患における肺マイクロバイオームの役割—系統的レビュー
Rare and Interstitial Lung Diseases-E-Book: Clinical Cases and Real-World Discussions
C Sorino, S Agati - 2024
… While it can occur in combination with other known interstitial entities (idiopathic pulmonaryfibrosis [IPF], nonspecific interstitial pneumonia [NSIP], and organizing pneumonia [OP]), it has also been described in lung with chronic, fibrosing …
- 希少間質性肺疾患 - 電子ブック: 臨床症例と実際の議論
24/02/22
[HTML] TGF-β1, pSmad-2/3, Smad-7, and β-Catenin Are Augmented in the Pulmonary Arteries from Patients with Idiopathic Pulmonary Fibrosis (IPF): Role in Driving …
AV Gaikwad, MS Eapen, S Dey, P Bhattarai… - Journal of Clinical Medicine, 2024
… ) is an active process in patients with idiopathic pulmonary fibrosis (IPF) contributing to arterial remodelling. Here, we aim to quantify drivers of EndMT in IPF patients compared to normal controls (NCs). Methods: Lung resections from thirteen …
- 特発性肺線維症（IPF）患者の肺動脈ではTGF-β1、pSmad-2/3、Smad-7、β-カテニンが増加する：内皮間葉移行（EndMT）の促進における役割
[PDF] Study design of BI 1015550 for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: a plain language summary
TM Maher, A Azuma, V Cottin, S Assassi… - Future Rare Diseases, 2024
… The FIBRONEER studies are testing the drug BI 1015550 as a treatment for people with idiopathic pulmonary fibrosis (IPF) and people with progressive pulmonary fibrosis (PPF). IPFis a severe lung disease where scar tissue builds up in …
- 特発性肺線維症および進行性肺線維症に対する BI 1015550 の研究デザイン: 平易な言葉での要約
The association between testosterone, estradiol, estrogen sulfotransferase and idiopathic pulmonary fibrosis: a bidirectional Mendelian randomization study
Q Xu, G Hu, Q Lin, M Wu, K Tang, Y Zhang, F Chen - 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive and irreversible pulmonary fibrosis. The etiology and pathogenesis of IPF are complex and not yet fully understood. Risk factors for …
SLC15A3 plays a crucial role in pulmonary fibrosis by regulating macrophage oxidative stress
J Luo, P Li, M Dong, Y Zhang, S Lu, M Chen, H Zhou… - Cell Death & Differentiation, 2024
… Idiopathic pulmonary fibrosis (IPF) is a fatal and irreversible disease with few effective treatments. Alveolar macrophages (AMs) are … The interplay of the genetic architecture, aging, and environmental factors in the pathogenesis of idiopathic …
- SLC15A3はマクロファージの酸化ストレスを調節することにより肺線維症において重要な役割を果たす
Genetics of autoimmune-associated interstitial lung diseases: A focus on rheumatoid arthritis
P Dieudé - Revista Colombiana de Reumatología, 2024
… The results of genetic studies support the hypothesis of a common genetic background between idiopathic pulmonary fibrosis (IPF) and RA-ILD, and more specifically RA-UIP, a subset of the disease associated with a poor prognosis …
- 自己免疫関連間質性肺疾患の遺伝学: 関節リウマチを中心に
SOX9-regulated matrix proteins predict poor outcomes in patients with COVID-19 and pulmonary fibrosis (preprint)
L Pearmain, E Jokl, K Simpson, L Birchall, Y Ou… - 2024
… serum samples from acute COVID19, post COVID19 and idiopathic pulmonary fibrosis(IPF) patient cohorts. Our hypothesis driven SOX9-… pulmonary fibrosis and its regulated pathways have diagnostic, prognostic and therapeutic potential in both …
24/02/20
[PDF] Radiological usual interstitial pneumonia pattern is associated with two-year mortality in patients with idiopathic pulmonary fibrosis
IG García-Manso, JA Jiménez, LH Blasco, EG Garrigós… - Heliyon, 2024
… The new diagnostic guidelines for idiopathicpulmonary fibrosis (IPF) did not rule out the … We applied the new criteria to a retrospective series of patients with IPF, assessing survival … taken at diagnosis in 146 patients with IPF, describing the …
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis
C Lee, SH Hyun, J Han, JH Shin, B Yoo, YS Lee… - European Respiratory …, 2024
… against pulmonary fibrosis has not yet been evaluated. This study aimed to determine whether ezetimibe has therapeutic potential against idiopathic pulmonary fibrosis. … In conclusion, our study presents ezetimibe as a potential novel …
- 特発性肺線維症の治療のためのエゼチミブの再配置
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis
S Ikeda, T Ogura, T Kato, H Kenmotsu, Y Agemi… - Annals of the American …, 2024
… precedence over IPF, and it was not practical to perform a biopsy for histopathologic examination of IPF. Therefore, the diagnosis of IPF in … With regard to the timing of the diagnosis of SCLC and IPF, this study allowed for both the …
- 特発性肺線維症を合併する小細胞肺がんに対するニンテダニブと化学療法
[PDF] A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review
RK Man, A Gogikar, A Nanda, LSN Janga, HG Sambe… - Cureus, 2024
… Idiopathic pulmonary fibrosis (IPF), which shares a radiographic pattern with the usual … As the cause of IPF is still unknown and there is no cure yet, presently, it is treated to delay … It was observed that the most accepted way of measuring the …
- 特発性肺線維症の治療におけるニンテダニブとピルフェニドンの有効性の比較：系統的レビュー
[PDF] Bosentan and ambrisentan in the treatment of idiopathic pulmonary fibrosis: a meta-analysis
HF LI, JX WANG, ZF XIE, LH LI, B Li, FF HUANG, J Li… - European Review for …, 2024
OBJECTIVE: The aim is to showcase the effectiveness and safety of bosentan or ambrisentan in individuals diagnosed with idiopathic pulmonary fibrosis (IPF) and offer fresh evidence for the management of this condition. MATERIALS AND …
[PDF] Characterization and evaluation of clinically relevant readouts in a pre-clinical model of Idiopathic Pulmonary Fibrosis (IPF)
A Murgo - 2024
… Research efforts in the last few years have reached important milestones in understanding the pathogenesis of IPF, making the concept "idiopathic" less compelling. The current paradigm suggests that IPF is an epithelial-fibroblastic …
- 特発性肺線維症 (IPF) の前臨床モデルにおける臨床的に関連する読み取り値の特性評価と評価
Thin-Section CT in the Categorization and Management of Pulmonary Fibrosis including Recently Defined Progressive Pulmonary Fibrosis
RM Shah, AM Kolansky, S Kligerman - Radiology: Cardiothoracic Imaging, 2024
… idiopathic pulmonary fibrosis (IPF) is the most common type of fibrotic lung disease, there are numerous other causes of pulmonaryfibrosis that … progression, this article reviews imaging features of pulmonary fibrosis and their significance in …
- 最近定義された進行性肺線維症を含む肺線維症の分類と管理における薄切片 CT
A Test to Comprehensively Capture the Known Genetic Component of Familial Pulmonary Fibrosis
J Villeneuve, É Tremblay, N Gaudreault… - American Journal of …, 2024
… The new genetic test was evaluated in 62 sporadic cases of idiopathic pulmonaryfibrosis (IPF). As expected in this population, we observed a low yield of disease-causing mutations. More importantly, 100% of targeted variants by the LDT were successfully …
- 家族性肺線維症の既知の遺伝的要素を包括的に捕捉する検査
e-Lung CT Biomarker Stratifies Patients at Risk of IPF Progression in a 52-Week Clinical Trial
A Devaraj, F Ottink, C Rennison-Jones, FX Blé, O Joly… - American Journal of …, 2024
… Since the successful pivotal studies of pirfenidone1 and nintedanib2 for idiopathicpulmonary fibrosis (IPF), several drugs have shown promise in early phase clinical trials3,4 only to fail on efficacy grounds in registrational studies5. With antifibrotic …
- e-Lung CT バイオマーカーは 52 週間の臨床試験で IPF 進行のリスクのある患者を層別化
Novel inhalable powder formulation of pirfenidone with sustained release properties to improve pulmonary deposition
Y Seto, G Suzuki, M Kato, H Sato, S Onoue - Journal of Drug Delivery Science and …, 2024
… of PFD and contribute to PFD medication for idiopathic pulmonary fibrosis with high efficacy and safety. … for IPF patients to achieve sufficient pharmacological efficacy; therefore, pharmacokinetic remediation to prolong retention of PFD in the …
- 肺沈着を改善するための徐放特性を備えたピルフェニドンの新しい吸入可能な粉末製剤
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
